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STATEMENT OF TRANSLATIONAL RELEVANCE
The oncogenic PI3K/Akt/mTOR pathway plays an important role in ovarian cancer, and therefore presents a suitable target for novel therapeutic approaches. This study evaluates the effects of dual PI3K and mTOR inhibition using NVP-BEZ235 on human ovarian carcinoma cells and on established ovarian tumor disease in an immunocompetent, transgenic mouse model. Approximately two thirds of all patients are diagnosed with advanced disease with a 5-year survival rate of about 30% (2) (3) (4) . The presence of primary platinum-resistant disease in 15% of all patients, and the development of platinum-resistance in recurrent ovarian cancer presents a major therapeutic challenge.
Recently, the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has been the focus of novel targeted therapeutic agents. This pathway plays an important role in many biological processes, including cell proliferation, growth, and survival (5- PI3K/Akt/mTOR pathway activation in ovarian cancer has been demonstrated in several studies (8) (9) (10) (11) (12) .
Overexpression of phosphorylated Akt in human ovarian tissue by
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immunohistochemistry is found in 50% of papillary serous ovarian cancers, and in up to 70-80% of endometrioid and clear cell adenocarcinomas of the ovary (12) . About 40% of primary ovarian tumors show amplification of the gene encoding the kinase active p110α subunit of PI3K (PIK3CA) (11) . Expression of phosphorylated 4E-BP1 in ovarian tumor specimens has been associated with a poor prognosis (13) .
NVP-BEZ235 is a novel therapeutic agent that targets two molecules in the PI3K/Akt/mTOR pathway, PI3K and mTOR (14) . It is an ATP-competitive pan-class I PI3K inhibitor that is effective against p110α with hotspot mutations, and likewise inhibits both mammalian target of rapamycin complex 1 (mTORC1) and mTORC2 (14) (15) (16) . Previous studies have demonstrated the efficacy of NVP-BEZ235 as an anti-tumor agent in vitro and in vivo in glioblastoma, multiple myeloma, melanoma, lymphomas, sarcomas, breast and lung cancer models (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . In a human sarcoma model, the drug was effective in inhibiting liver metastasis (24, 25) . NVP-BEZ235 was shown to decrease the population of cells enriched in prostate cancer progenitors and their sphere-forming capacity (27) . NVP-BEZ235 treatment has demonstrated anti-tumor efficacy in combination with chemotherapeutic agents and ionizing radiation (18, 20-22, 25, 28) . The effects of this dual PI3K/mTOR inhibitor have been attributed to the induction of cell cycle arrest, apoptosis, and to its anti-angiogenic properties (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) 25) .
In the present study, we demonstrate that dual inhibition of PI3K and mTOR using NVP-BEZ235 inhibits cell growth in a panel of 18 cisplatin-sensitive and cisplatin-resistant human ovarian carcinoma cell lines. The presence of PI3K activating mutations or Pten deletions and elevated levels of p4E-BP1 protein were significantly correlated with increased sensitivity to NVP-BEZ235. In a transgenic, immunocompetent mouse model of ovarian cancer, NVP-BEZ235 inhibited PI3K/Akt/mTOR pathway signaling in tumor tissue and prolonged the 
MATERIALS AND METHODS
Cell Lines
The cell lines A2780 and IGROV1 were obtained from the National Cancer Institute ).
Immunoblot Assay
NVP-BEZ235 and RAD001 were generously provided by NOVARTIS Pharmaceuticals, was expressed relative to the corresponding level of β-actin.
Cell Proliferation Assays
Cells seeded in 96-(XTT) or 24-(Vi-CELL) well plates were incubated overnight, followed by drug treatment for 72h at 37 o C. Cell viability was assessed according to standard multi-mode microplate reader using the Gen5™ data analysis software (Bio-Tek Instruments).
Cell Migration Assay
Cell migration assays were performed using the Boyden transwell dual chamber system. Cells and counterstained with hematoxylin.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism, Version 4.00c for 
RESULTS
NVP-BEZ235 inhibits PI3K/Akt/mTOR pathway signaling in human ovarian cancer cell lines
We examined the effect of dual PI3K/mTOR inhibition using NVP-BEZ235 on PI3K/Akt/mTOR pathway signaling in three human ovarian cancer cell lines. Treatment of IGROV1, SKOV3 or OVCAR5 cells with NVP-BEZ235 decreased phosphorylation of Akt (pAkt), S6 (pS6) and 4E-BP1 (p4E-BP1) in a dose-dependent manner in all cell lines ( Figure   1A ). In contrast, mTOR inhibition alone using RAD001 treatment decreased pS6 and p4E-BP1, while Akt phosphorylation levels increased in SKOV3 and OVCAR5 cells, and remained unchanged in IGROV1 cells ( Figure 1B ). This latter observation is consistent with the mTOR inhibition mediated lack of the negative feedback loop on p70S6K/insulin receptor substrate (IRS) signaling that leads to increased Akt phosphorylation.
NVP-BEZ235 inhibits proliferation of ovarian cancer cell lines
To study the effects of NVP-BEZ235 on cell proliferation, we used an ovarian cancer cell line panel of human (A2780, ES-2, HEYC2, IGROV1, MCAS, OAW42, OV167, OV207, OV2008, OVCAR5, PE01, SKOV3 and TOV-112D) and murine (MOVCAR18) cell lines.
NVP-BEZ235 decreased cell proliferation in all cell lines in a dose-dependent manner ( Figure   2A ). In contrast, the decrease in cell proliferation induced by RAD001 was markedly less compared to NVP-BEZ235 at equimolar concentrations.
We next studied the relationship between the presence of activating mutations in PI3K or 
drug that results in a decrease of cell proliferation by 50%) for the effect of NVP-BEZ235 on cell proliferation was calculated for each cell line. Cell lines with an IC 50 < 100 nM were considered to be highly sensitive to drug treatment, compared to cell lines with an IC 50 > 100 nM, which were considered less sensitive. Figure 2B shows that all cell lines with PI3K activating We further examined whether the relative levels of pAkt, pS6 or p4E-BP1 protein, as expressed by each cell line under non-stimulated conditions, correlate with the response to NVP-BEZ235 ( Figure 2C ). We found that cell lines with high levels of p4E-BP1 protein showed a greater sensitivity to NVP-BEZ235 than cell lines with low p4E-BP1 levels. The correlation between the relative p4E-BP1 protein levels and the IC 50 for NVP-BEZ235 was statistically significant (r 2 = 0.46, p < 0.01). In contrast, we could not demonstrate a correlation between relative levels of pAkt or pS6 and sensitivity of cells to NVP-BEZ235 (pAkt: r 2 = 0.000006, p=0.99 ; pS6: r 2 = 0.10, p=0.28). These data suggest that p4E-BP1 protein levels might serve as a molecular predictor of response to NVP-BEZ235.
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More importantly, the median survival of mice treated with NVP-BEZ235 was significantly longer compared to survival of control animals based on Kaplan Meier survival curve analysis (105 days vs. 58 days, respectively; p < 0.01) ( Figure 3C ). The hazard ratio for death in the control group was 4.02 (95% CI = 1. 47 -10.98 ). These results demonstrate that NVP-BEZ235 was able to control intra-peritoneal tumor disease in mice, resulting in significantly improved survival.
NVP-BEZ235 inhibits proliferation of cisplatin-resistant human ovarian cancer cells
To examine the efficacy of NVP-BEZ235 in cisplatin-resistant cells, we developed cisplatin-resistant, isogenic clones of SKOV3 and OVCAR5 cells (designated SKOV3-CisR and OVCAR5-CisR, respectively). In addition, we used two pairs of cisplatin-sensitive (A2780 and OV2008) and their cisplatin-resistant clones (CP70 and C13*, respectively) previously established by other investigators (32) .
The level of cisplatin resistance was assayed using cell proliferation assays ( Figure 4A ).
SKOV3 cells were about 20 fold more sensitive to cisplatin than SKOV3-CisR cells (IC 50 = 1.4 + 0.2 μg/ml vs. 28.1 + 0.4 μg/ml respectively), while OVCAR5 and OVCAR5-CisR cells showed the greatest difference in cisplatin sensitivity (IC 50 = 1.8 + 0.1 μg/ml vs 245 + 76 μg/ml).
We confirmed differences in cisplatin sensitivity for A2780 and CP70 (IC 50 = 0.32 + 0.01 μg/ml vs. 2.17 + 0.37 μg/ml, respectively), and OV2008 and C13* cells (IC 50 = 0.059 + 0.002 μg/ml vs. 0.49 + 0.06 μg/ml, respectively). 
NVP-BEZ235 sensitizes ovarian cancer cells to cisplatin
We next determined whether NVP-BEZ235 could increase the cytotoxic effects of We next investigated whether the cisplatin sensitizing effect of NVP-BEZ235 requires continuous exposure to cisplatin, or can also be demonstrated with shorter cisplatin treatment.
We therefore first determined the sensitivity of cisplatin-resistant and cisplatin-sensitive cells to 2 hours of cisplatin treatment (Supplementary Figure 1A) . We then performed all combination experiments using 2 hours exposure to cisplatin and continuous treatment with NVP-BEZ235.
The results confirmed that NVP-BEZ235 is able to sensitize cisplatin-resistant (Supplementary 
SKOV3-CisR and CP70 cells, inhibition of migration required concentrations of NVP-BEZ235
higher than 50 nM ( Figure 5C ).
DISCUSSION
This study is the first to provide evidence for the efficacy of the novel dual PI3K/mTOR inhibitor NVP-BEZ235 in preclinical models of ovarian cancer. We demonstrate that NVP-BEZ235 effectively blocked PI3K/Akt/mTOR pathway signaling, decreased cell proliferation, and sensitized cells to cisplatin treatment. In immunocompetent mice with established ovarian tumor disease, oral administration of NVP-BEZ235 decreased pAkt, p4E-BP1 and Ki67 in tumor tissue, and resulted in significantly longer survival compared to control animals. Importantly, NVP-BEZ235 was effective in both platinum-sensitive and platinum-resistant cell models.
Targeting the PI3K/Akt/mTOR pathway in cancer disease has been a focus of drug development recently, but the optimal therapeutic strategy has yet to be identified. Prior studies including studies from our laboratory in preclinical models of ovarian cancer have mainly investigated the effects of either PI3K or mTOR inhibition alone (8, (33) (34) (35) (36) (37) (38) (39) (40) . For example, the mTOR inhibitor RAD001 showed a delay in the onset and progression of tumor growth in a transgenic ovarian cancer mouse model, and clinical trials with RAD001 are ongoing (38, 41) .
However, mTOR inhibition alone can increase Akt phosphorylation levels as demonstrated in our study and described by others prior (42) (43) (44) . This effect is attributed to the mTOR inhibitionmediated lack of the negative feedback loop on p70S6K/insulin receptor substrate (IRS) signaling and subsequent increase in Akt phosphorylation. In contrast to mTOR inhibition alone, we showed that dual PI3K/mTOR inhibition using NVP-BEZ235 reduced, rather than increased, Ovarian cancer is a chemotherapy-sensitive disease, and about 85% of patients respond to first line treatment with platinum-based chemotherapeutic agents. However, the presence of primary platinum-resistant disease, and the development of platinum resistance in recurrent ovarian cancer presents a major therapeutic challenge. Unfortunately, at the current time, there is no truly effective treatment strategy for platinum-resistant disease. We found that NVP- In summary, our data show that dual PI3K/Akt/mTOR inhibition using NVP-BEZ235 in ovarian cancer models has growth-inhibitory and anti-tumor effects, and is able to sensitize cells to platinum agents. We propose NVP-BEZ235 treatment as a promising therapeutic strategy in ovarian cancer patients that might be effective even in the presence of platinum resistance. 
